The risk of atherosclerotic cardiovascular disease is increased in people with HIV infection, including young patients and those with few traditional cardiovascular risk factors. The increased risk of cardiovascular disease among people living with HIV is due to accelerated atherosclerosis, caused by chronic inflammation and immune dysregulation. The measurement of coronary calcium using plain computed tomography is a subclinical indicator of coronary atherosclerosis and is associated with the risk of cardiovascular events and mortality in the general population.
Patients who have been diagnosed with HIV infection for more than 6 months
Undetectable viral load
Patients who have previously taken statins
Patients with chronic ischemic heart disease that has required stenting or revascularization
A multicenter study that will include patients diagnosed with HIV from three hospitals in León: the Mexican Social Security Institute (2) and CAPASITS León.
Cohort
Prospective
Simple coronary CT scan
Diagnostic testAll patients will undergo a standard coronary CT scan to measure coronary calcium
Coronary calcium
The result is expressed in points using the Agatston scale and indicates the level of risk: * 0 points: No calcium. Very low risk. No significant coronary artery disease apparent at the time of the study. * 1 to 99 points: Mild calcified plaque. There is a mild risk of heart disease. * 100 to 300 points: Moderate plaque. Moderate risk of heart disease. * More than 300 points: Extensive plaque. High risk of heart disease and heart attack.
Cardiovascular risk
For every patient who meets the inclusion criteria, cardiovascular risk will be assessed using the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations estimate 10-year and 30-year risk for total cardiovascular disease (CVD), including atherosclerotic CVD (ASCVD) and heart failure. It is classified as follows: * Low risk: Less than 5% * Borderline risk: 5% to 7.4% * Intermediate risk: 7.5% to 19.9% * High risk: 20% or more
Major adverse cardiovascular events
The occurrence of major adverse cardiovascular events will be assessed: acute myocardial infarction, stroke, and cardiovascular death
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
